What top creators are saying about uniQure N.V.(QURE)

Used as an example of a biotech stock that fell from about $37 to roughly $7 and later recovered toward the mid-$20s. It illustrated that a sharp decline does not by itself determine recovery; this was not a recommendation.

The speaker remained optimistic, saying the discussed news should not affect regulatory review, but would consider waiting for a pullback before buying again.

The host sold at $20 for a profit and viewed the stock as a regulatory catalyst trade. They said the news should not change the review, but acknowledged investor nervousness and were unsure whether to buy again on a pullback.

The speaker characterized the Huntington's disease data as weak, while acknowledging possible FDA approval and expected four-year data; he said he was not short.

Experienced significant upward movement following an FDA policy shift favoring gene therapy treatments.

A highly speculative, high-risk, high-reward investment whose future is almost entirely dependent on a regulatory outcome with the FDA. A positive catalyst could be the FDA reversing its decision on the company's data submission.

Mentioned briefly as a biotech stock the speaker likes and considers a 'long' position.

Described as a 'big win' for the speaker's portfolio, with a continued positive outlook expressed as 'I like Cure. It's gone up a lot.'